Casi Pharma-Partnered BioInvent's Lead Cancer Program Gets FDA Orphan Drug Tag

The FDA has granted Orphan Drug Designation to BioInvent International AB's BOVNF BI-1206, an anti-FcyRllB antibody, for follicular lymphoma (FL) the most common form of Non-Hodgkin lymphoma (NHL).

  • BioInvent is a collaborating partner of CASI Pharmaceuticals Inc CASI.
  • BI-1206 is BioInvent's lead drug candidate and is currently being investigated in two Phase 1/2 trials. 
  • One trial is evaluating the BI-1206 combination with rituximab for Non-Hodgkin lymphoma in patients who have relapsed or are refractory to rituximab. 
  • A second Phase 1/2 trial is investigating BI-1206 in combination with Merck & Co Inc MRK anti-PD1 therapy Keytruda (pembrolizumab) in solid tumors.
  • Price Action: CASI shares are up 4.21% at $0.72 during the premarket session on the last check Thursday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareSmall CapFDAMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!